Long-term outcomes of elderly patients receiving continuous flow left ventricular support

Area of Science:

• Cardiology
• Medical Devices
• Geriatrics

Background:

• Heart failure affects over 6 million Americans, with 80% of patients older than 65.
• Heart transplantation, the gold standard, is less accessible to elderly patients (only 18.5% are 65+).
• Continuous-flow left ventricular assist devices (CF-LVADs) provide a safe and effective treatment for advanced heart failure.

Purpose of the Study:

• To evaluate the long-term outcomes of elderly patients receiving CF-LVADs.
• To compare the safety and efficacy of CF-LVADs in older adults versus younger patients.

Main Methods:

• Retrospective analysis of elderly patients who received CF-LVADs.
• Characterization of long-term clinical outcomes and complication rates.

Main Results:

• Elderly patients demonstrated comparable operative results to younger counterparts.
• Low rates of complications were observed up to 6 years of CF-LVAD support.
• Outcomes in elderly patients were comparable to those in younger patient groups.

Conclusions:

• CF-LVADs are a safe and effective alternative for elderly patients with advanced heart failure.
• This therapy provides a viable option for patients less likely to receive a heart transplant.
• Long-term support with CF-LVADs is feasible and beneficial for the aging heart failure population.